Stock Market Update - December 30, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. EKSO - Ekso Bionics Holdings, Inc.
Price: $10.58 | Change: +93.77% ($5.12)
EKSO experienced a significant surge, gaining over 93.77% in late 2025. This impressive move was triggered by Ekso Bionics' announcement of a proposed business combination with Applied Digital's cloud computing business.
The strategic goal is to form a new company called ChronoScale Corporation, which will focus on building an accelerated compute platform for artificial intelligence (AI) workloads. This effectively pivots Ekso Bionics from its traditional exoskeleton business into the rapidly expanding AI and data center infrastructure market. Interestingly, under the proposed terms, Applied Digital is expected to own a substantial 97% of the new ChronoScale Corporation.
2. AEHL - Antelope Enterprise Holdings Limited
Price: $2.18 | Change: +92.92% ($1.05)
AEHL saw a significant jump, gaining an impressive 92.92% around December 31, 2025. This surge followed a key corporate move: Antelope Enterprise Holdings Limited announced a change to its fiscal year-end, shifting it from December 31 to September 30 starting with fiscal year 2026. This strategic adjustment was made to better match their financial reporting with their business operations, which often signals improved planning and management efficiency to investors.
But there's more to AEHL than just financial calendar tweaks. The company has a diverse portfolio, including natural gas power generation and a significant stake in China's booming livestreaming e-commerce sector. Plus, they secured up to $50 million in financing earlier in 2025 specifically for a Bitcoin acquisition plan. This mix of traditional energy, digital commerce, and a foray into crypto, combined with its nature as a typically volatile microcap stock, fueled significant market interest and its notable rise.
3. AFJK - Aimei Health Technology Co., Ltd
Price: $82.58 | Change: +89.19% ($38.93)
AFJK experienced an 89.19% gain, though its journey was marked by extreme volatility. This surge, which saw the stock rocket over 1,000% at one point before a sharp 44-46% decline, was all about a merger extension. Aimei Health Technology (AFJK), a Special Purpose Acquisition Company (SPAC) looking to combine with another business, announced the thirteenth extension of its planned merger with Chinese hydrogen energy company United Hydrogen Group, pushing the deadline to December 2026.
To secure this extra year, Aimei Health made a small deposit into its trust account. The repeated delays underscore the complexity and ongoing uncertainty surrounding this long-awaited deal. It’s this persistent unpredictability that largely fuels the dramatic swings in AFJK's stock, offering a vivid example of how merger news, especially repeated extensions, can send a stock on a rollercoaster ride.
4. PFSA - Profusa, Inc. Common Stock
Price: $0.1218 | Change: +78.33% ($0.0535)
PFSA experienced an impressive 78.33% gain around December 31, 2025, following the announcement of a significant restructuring of its Senior Secured Convertible Note. This strategic financial maneuver was undertaken to provide Profusa with greater repayment flexibility and to mitigate potential dilution for existing shareholders.
Key aspects of the restructuring included raising the conversion floor price of the convertible notes, designed to reduce their dilutive impact. The company also eliminated mandatory cash and equity amortization payments that were set to begin in early 2026, granting it more immediate financial flexibility. Profusa's leadership stated that this enhanced flexibility would allow them to dedicate resources towards accelerating growth initiatives, forging new partnerships, and bolstering inventory in the upcoming year.
5. DLXY - Delixy Holdings Limited Ordinary Shares
Price: $1.41 | Change: +67.86% ($0.57)
DLXY soared by a remarkable 67.86% as 2025 wrapped up. This significant jump came after Delixy Holdings Limited, a Singapore-based company trading oil-related products, released its unaudited financial results for the first six months of the year.
Despite a dip in revenue to $102.0 million, mainly due to lower oil prices and weak demand, the company showcased impressive financial management. Delixy managed to boost its net income to $560,000, up from $450,000 in the prior year. This improved profitability was primarily driven by substantial cuts to general and administrative expenses, which significantly increased its operating profit and earnings per share.
What truly caught investors' eyes was how the company strengthened its financial health. Total assets more than doubled, and shareholders’ equity grew significantly. This demonstrated Delixy's operational efficiency and an enhanced capital base, which resonated positively with the market despite the challenging revenue environment.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.